Laurus Labs Ltd

Laurus Labs Ltd

₹ 436 0.74%
24 Apr 2:15 p.m.
About

Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership
position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing.
Laurus employs 6500+ people, including around 1050+ scientists at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. [1]

Key Points

Integrated Pharma Company[1] Laurus Labs is a fully integrated pharmaceutical and biotechnology company, with a leadership position in Active Pharmaceutical Ingredients (APIs) in selected high-growth therapeutic areas and a major focus on anti-retroviral, Hepatitis C, and oncology drugs.

  • Market Cap 23,515 Cr.
  • Current Price 436
  • High / Low 471 / 279
  • Stock P/E 125
  • Book Value 74.8
  • Dividend Yield 0.46 %
  • ROCE 22.8 %
  • ROE 21.4 %
  • Face Value 2.00

Pros

  • Company has delivered good profit growth of 36.3% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 29.4%

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
1,288 1,412 1,278 1,203 1,029 1,425 1,539 1,576 1,545 1,381 1,182 1,224 1,195
862 940 883 858 743 1,028 1,085 1,127 1,141 1,095 1,015 1,037 1,014
Operating Profit 426 472 395 345 285 397 454 449 404 286 167 188 181
OPM % 33% 33% 31% 29% 28% 28% 30% 28% 26% 21% 14% 15% 15%
7 5 6 3 5 1 2 1 1 2 4 2 2
Interest 17 22 27 22 23 31 29 40 43 53 39 42 51
Depreciation 52 54 59 63 64 66 71 82 84 87 91 93 98
Profit before tax 364 401 316 263 204 302 356 328 278 147 41 54 35
Tax % 25% 26% 24% 22% 24% 23% 29% 29% 27% 27% 30% 27% 27%
273 297 242 204 155 232 252 233 203 105 27 37 23
EPS in Rs 5.08 5.53 4.50 3.76 2.86 4.29 4.68 4.33 3.77 1.91 0.46 0.69 0.43
Raw PDF
Upcoming result date: tomorrow

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
1,160 1,327 1,778 1,905 2,056 2,292 2,832 4,814 4,936 6,041 4,982
951 1,126 1,415 1,497 1,642 1,935 2,266 3,262 3,512 4,448 4,161
Operating Profit 208 200 362 408 414 357 565 1,552 1,424 1,592 822
OPM % 18% 15% 20% 21% 20% 16% 20% 32% 29% 26% 16%
9 34 4 32 29 15 5 23 14 6 10
Interest 64 106 111 100 80 88 90 68 102 165 186
Depreciation 33 62 86 106 125 164 187 205 251 324 369
Profit before tax 121 67 169 234 237 120 294 1,301 1,084 1,109 276
Tax % 20% -2% 21% 19% 29% 22% 13% 24% 23% 28%
97 68 134 190 168 94 255 984 832 793 193
EPS in Rs 12.64 8.81 16.97 3.60 3.16 1.76 4.77 18.33 15.40 14.67 3.49
Dividend Payout % 0% 0% 2% 8% 9% 17% 10% 11% 13% 14%
Compounded Sales Growth
10 Years: %
5 Years: 24%
3 Years: 29%
TTM: -18%
Compounded Profit Growth
10 Years: %
5 Years: 36%
3 Years: 46%
TTM: -80%
Stock Price CAGR
10 Years: %
5 Years: 41%
3 Years: -2%
1 Year: 47%
Return on Equity
10 Years: %
5 Years: 25%
3 Years: 29%
Last Year: 21%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 15 16 16 106 106 106 107 107 107 108 108
Reserves 281 640 774 1,225 1,377 1,452 1,663 2,490 3,244 3,930 3,922
Preference Capital 62 67 67 0 0 0 0 0 0 0
543 821 1,028 842 980 1,036 1,079 1,482 1,777 2,015 2,134
434 412 406 481 554 737 901 1,671 1,840 1,608 1,893
Total Liabilities 1,273 1,888 2,224 2,653 3,017 3,331 3,750 5,751 6,968 7,660 8,058
499 801 1,021 1,230 1,481 1,629 1,726 2,171 2,652 3,409 3,730
CWIP 116 110 70 143 163 110 67 362 813 551 444
Investments 0 7 7 3 3 3 3 3 31 50 94
658 970 1,126 1,277 1,369 1,589 1,953 3,214 3,472 3,651 3,790
Total Assets 1,273 1,888 2,224 2,653 3,017 3,331 3,750 5,751 6,968 7,660 8,058

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
121 -65 182 332 342 298 347 733 911 994
-312 -397 -312 -289 -384 -253 -221 -941 -914 -997
203 486 103 -54 42 -45 -128 255 30 -27
Net Cash Flow 12 24 -27 -10 1 -0 -1 47 27 -30

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 61 78 91 109 101 113 102 99 100 96
Inventory Days 165 210 176 186 201 201 234 266 293 222
Days Payable 114 102 90 96 107 144 159 199 146 94
Cash Conversion Cycle 112 186 178 199 195 170 177 166 247 224
Working Capital Days 61 118 117 126 124 115 117 121 128 133
ROCE % 14% 16% 16% 14% 8% 14% 40% 26% 23%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
27.30% 27.30% 27.27% 27.27% 27.27% 27.27% 27.20% 27.20% 27.20% 27.20% 27.18% 27.18%
21.54% 22.82% 22.08% 22.45% 21.98% 22.67% 21.90% 22.42% 22.52% 24.03% 25.39% 25.98%
4.15% 4.81% 6.90% 7.93% 9.11% 9.34% 9.51% 9.74% 10.36% 11.01% 11.13% 11.78%
47.01% 45.06% 43.76% 42.36% 41.65% 40.74% 41.38% 40.64% 39.93% 37.75% 36.30% 35.07%
No. of Shareholders 2,99,2573,94,0534,67,4194,27,4654,07,1863,90,6954,23,9314,18,6154,17,9774,02,6403,82,8803,56,830

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls